356 related articles for article (PubMed ID: 34659200)
1. Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Autoimmunity 1 Year Later: The Era of Vaccines.
Picchianti Diamanti A; Rosado MM; Nicastri E; Sesti G; Pioli C; Laganà B
Front Immunol; 2021; 12():708848. PubMed ID: 34659200
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.
Geisen UM; Berner DK; Tran F; Sümbül M; Vullriede L; Ciripoi M; Reid HM; Schaffarzyk A; Longardt AC; Franzenburg J; Hoff P; Schirmer JH; Zeuner R; Friedrichs A; Steinbach A; Knies C; Markewitz RD; Morrison PJ; Gerdes S; Schreiber S; Hoyer BF
Ann Rheum Dis; 2021 Oct; 80(10):1306-1311. PubMed ID: 33762264
[TBL] [Abstract][Full Text] [Related]
3. Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series.
Connolly CM; Boyarsky BJ; Ruddy JA; Werbel WA; Christopher-Stine L; Garonzik-Wang JM; Segev DL; Paik JJ
Ann Intern Med; 2021 Sep; 174(9):1332-1334. PubMed ID: 34029488
[No Abstract] [Full Text] [Related]
4. COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology.
Park JK; Lee EB; Shin K; Sung YK; Kim TH; Kwon SR; Lee MS; Hong SJ; Choi BY; Lee SS; Back HJ;
J Korean Med Sci; 2021 Mar; 36(12):e95. PubMed ID: 33783147
[TBL] [Abstract][Full Text] [Related]
5. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.
Braun-Moscovici Y; Kaplan M; Braun M; Markovits D; Giryes S; Toledano K; Tavor Y; Dolnikov K; Balbir-Gurman A
Ann Rheum Dis; 2021 Oct; 80(10):1317-1321. PubMed ID: 34144967
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.
Bonelli MM; Mrak D; Perkmann T; Haslacher H; Aletaha D
Ann Rheum Dis; 2021 Oct; 80(10):1355-1356. PubMed ID: 33958323
[No Abstract] [Full Text] [Related]
7. Interleukin-1 Inhibitors and Vaccination Including COVID-19 in Inflammatory Rheumatic Diseases: A Nonsystematic Review.
Atagündüz P; Keser G; Soy M
Front Immunol; 2021; 12():734279. PubMed ID: 35154066
[TBL] [Abstract][Full Text] [Related]
8. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.
Spiera R; Jinich S; Jannat-Khah D
Ann Rheum Dis; 2021 Oct; 80(10):1357-1359. PubMed ID: 33975857
[No Abstract] [Full Text] [Related]
9. SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future.
Winthrop KL; Whitley RJ; Aletaha D
Ann Rheum Dis; 2021 Oct; 80(10):1249-1251. PubMed ID: 34518198
[No Abstract] [Full Text] [Related]
10. Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development.
Ita K
Arch Med Res; 2021 Jan; 52(1):15-24. PubMed ID: 32950264
[TBL] [Abstract][Full Text] [Related]
11. Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system.
de Queiroz NMGP; Marinho FV; Chagas MA; Leite LCC; Homan EJ; de Magalhães MTQ; Oliveira SC
Microbes Infect; 2020; 22(10):515-524. PubMed ID: 32961274
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.
Tscherne A; Schwarz JH; Rohde C; Kupke A; Kalodimou G; Limpinsel L; Okba NMA; Bošnjak B; Sandrock I; Odak I; Halwe S; Sauerhering L; Brosinski K; Liangliang N; Duell E; Jany S; Freudenstein A; Schmidt J; Werner A; Gellhorn Serra M; Klüver M; Guggemos W; Seilmaier M; Wendtner CM; Förster R; Haagmans BL; Becker S; Sutter G; Volz A
Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34162739
[TBL] [Abstract][Full Text] [Related]
13. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
[TBL] [Abstract][Full Text] [Related]
14. Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-2.
Sharma D
Expert Rev Vaccines; 2021 Sep; 20(9):1051-1057. PubMed ID: 34313516
[TBL] [Abstract][Full Text] [Related]
15. Coronavirus Disease 2019 Vaccination Is Associated With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Death in Liver Transplant Recipients.
John BV; Deng Y; Khakoo NS; Taddei TH; Kaplan DE; Dahman B
Gastroenterology; 2022 Feb; 162(2):645-647.e2. PubMed ID: 34758352
[No Abstract] [Full Text] [Related]
16. Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy.
Wang Y; Yang C; Song Y; Coleman JR; Stawowczyk M; Tafrova J; Tasker S; Boltz D; Baker R; Garcia L; Seale O; Kushnir A; Wimmer E; Mueller S
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34193524
[TBL] [Abstract][Full Text] [Related]
17. [Vaccination against SARS-CoV-2 in patients with multiple sclerosis].
Costa Frossard-França L; García-Domínguez JM; Moreno-Torres I; Fortún J; Villar LM; Meca-Lallana V
Rev Neurol; 2021 Apr; 72(7):250-260. PubMed ID: 33764494
[TBL] [Abstract][Full Text] [Related]
18. Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection.
Li M; Guo J; Lu S; Zhou R; Shi H; Shi X; Cheng L; Liang Q; Liu H; Wang P; Wang N; Wang Y; Fu L; Xing M; Wang R; Ju B; Liu L; Lau SY; Jia W; Tong X; Yuan L; Guo Y; Qi H; Zhang Q; Huang Z; Chen H; Zhang Z; Chen Z; Peng X; Zhou D; Zhang L
Front Immunol; 2021; 12():697074. PubMed ID: 34262569
[TBL] [Abstract][Full Text] [Related]
19. Coronavirus Disease 2019 Vaccine Development: An Overview.
Sumirtanurdin R; Barliana MI
Viral Immunol; 2021 Apr; 34(3):134-144. PubMed ID: 32985963
[TBL] [Abstract][Full Text] [Related]
20. Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques.
Marlin R; Godot V; Cardinaud S; Galhaut M; Coleon S; Zurawski S; Dereuddre-Bosquet N; Cavarelli M; Gallouët AS; Maisonnasse P; Dupaty L; Fenwick C; Naninck T; Lemaitre J; Gomez-Pacheco M; Kahlaoui N; Contreras V; Relouzat F; Fang RHT; Wang Z; Ellis J; Chapon C; Centlivre M; Wiedemann A; Lacabaratz C; Surenaud M; Szurgot I; Liljeström P; Planas D; Bruel T; Schwartz O; Werf SV; Pantaleo G; Prague M; Thiébaut R; Zurawski G; Lévy Y; Grand RL
Nat Commun; 2021 Sep; 12(1):5215. PubMed ID: 34471122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
